Prostacyclin's Effect on Platelet Responsiveness
Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.
1 other identifier
interventional
23
1 country
1
Brief Summary
The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Sep 2007
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2008
CompletedFirst Submitted
Initial submission to the registry
April 23, 2009
CompletedFirst Posted
Study publicly available on registry
April 29, 2009
CompletedApril 29, 2009
April 1, 2009
8 months
April 23, 2009
April 28, 2009
Conditions
Keywords
Study Arms (2)
1 prostacyclin group
ACTIVE COMPARATORprostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
2 heparin group
ACTIVE COMPARATORunfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
Interventions
prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
Eligibility Criteria
You may qualify if:
- critically patients ill patients with acute kidney failure (AKI) needing renal replacement therapy
You may not qualify if:
- therapy with aspirin or other non-steroidal anti-inflammatory drugs in the previous 7 days
- concomitant treatment with other extracorporeal organ-assist devices any other drug affecting coagulation or platelets
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Policlinico Gemelli
Rome, 00168, Italy
Related Publications (1)
Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012467. doi: 10.1002/14651858.CD012467.pub3.
PMID: 33314078DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Massimo Antonelli, MD
Istituto Anestesia e Rianimazione Università Cattolica Policlinico Gemelli
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 23, 2009
First Posted
April 29, 2009
Study Start
September 1, 2007
Primary Completion
May 1, 2008
Study Completion
May 1, 2008
Last Updated
April 29, 2009
Record last verified: 2009-04